MGP Regulates Perivascular Adipose-Derived Stem Cells Differentiation Toward Smooth Muscle Cells Via BMP2/SMAD Pathway Enhancing Neointimal Formation

Hui Ni1*, Chang Liu1*, Yuwen Chen1, Yunrui Lu1, Yongli Ji1, Meixiang Xiang1, and Yao Xie1

Abstract
Perivascular adipose-derived stem cells (PV-ADSCs) could differentiate into smooth muscle cells (SMCs), participating in vascular remodeling. However, its underlying mechanism is not well explored. Our previous single-cell RNA-sequencing dataset identified a unique expression of matrix Gla protein (MGP) in PV-ADSCs compared with subcutaneous ADSCs. MGP involves in regulating SMC behaviors in vascular calcification and atherosclerosis. In this study, we investigated MGP’s role in PV-ADSCs differentiation toward SMCs in vitro and in vascular remodeling in vivo. PV-ADSCs were isolated from perivascular regions of mouse aortas. Quantitative reverse transcription–polymerase chain reaction (qRT-PCR), Western blot, and immunofluorescence confirmed higher MGP expression in PV-ADSCs. The MGP secretion increased along PV-ADSCs differentiation toward SMCs in response to transforming growth factor–beta 1 (TGF-β1). Lentivirus knockdown of MGP markedly promoted the bone morphogenetic protein 2 (BMP2) expression and phosphorylation of SMAD1/5/8 in PV-ADSCs, subsequently inhibiting its differentiation toward SMCs. Such inhibition could be partially reversed by further application of BMP2 inhibitors. On the contrary, exogenous MGP inhibited BMP2 expression and SMAD1/5/8 phosphorylation in PV-ADSCs, thereby promoting its differentiation toward SMCs. Transplantation of cultured PV-ADSCs, which was pretreated by MGP knockdown, in mouse femoral artery guide-wire injury model significantly alleviated neointimal hyperplasia. In conclusion, MGP promoted the differentiation of PV-ADSCs toward SMCs through BMP2/SMAD-mediated signaling pathway. This study offers a supplement to the society of perivascular tissues and PV-ADSCs.

Keywords
MGP, PV-ADSCs, SMCs, cell differentiation, BMP2/SMAD pathway

Introduction
Atherosclerotic cardiovascular diseases (ASCVDs) are the major cause of mortality in the world. Neointimal hyperplasia is the prominent pathological process in ASCVDs, where phenotypic switching of vascular smooth muscle cells (SMCs) and macrophages are initially believed as key participants. Later studies confirmed the importance of vascular adventitial progenitor cells in the differentiation toward vascular lineages and in neointima formation after vascular injury. For example, adventitial LY6A+ cells could migrate to the intima and then differentiate to SMCs, promoting neointimal hyperplasia1. Adipose tissues surround the arteries except vasculatures in the central nervous system. Surprisingly, perivascular adipose tissues have long been ignored.
Adipose tissue is well known for its role in metabolism, inflammation, and adipokine release. Until 2001, the Zuk group first isolated adipose-derived stem cells (ADSCs) from subcutaneous adipose tissue by enzymatic digestion. In 2008, mesenchymal stem cells (MSCs) were identified in the perivascular tissue, which could differentiate into multilineages including SMCs and endothelial cells (ECs). ADSCs from different origins displayed distinctive characteristics. Subcutaneous adipose-derived stem cells (SUB-ADSCs) could give rise to tube-forming ECs in Matrigel and improve the blood perfusion of ischemic limbs in mice. Two recent researches confirmed the existence of perivascular adipose-derived stem cells (PV-ADSCs) by immuno-fluorescence, flow cytometry, and scRNA-sequencing. Gu et al. revealed that PV-ADSCs could differentiate into SMCs in vivo and enhance neointimal hyperplasia in mouse vein graft model. Pan et al. discovered that PV-ADSCs from older mice could develop more neointima than young PV-ADSCs in guide-wire artery injury model. ADSCs expressedMSC-like markers such as LY6A, PDGFRA, THY1, CD34, and so on. By applying genetic lineage tracing mice, Tang et al. demonstrated that aortic adventitial LY6A+/PDGFRA+ cells not LY6A+/PDGFRA- cells could differentiate into SMCs in vivo. However, the mechanism of PV-ADSCs differentiation toward SMCs was unclear.

Matrix Gla protein (MGP) is a vitamin K–dependent secreted protein, which is closely associated with osteogenic differentiation, atherosclerosis, and vascular calcification. Accumulating evidence revealed the importance of MGP in vascular lineages. MGP promotes ECs proliferation, migration, tubeformation, and regulated SMCs differentiation and maturation. MGP knockout in SMCs significantly decreased ACTA2, TAGLN, and MYH11 expression while it upregulated osteogenic-related protein RUNX2. A recent study showed that MGP was involved in the ADSCs differentiation toward mature adipocytes. Our previous scRNA dataset displayed that PV-ADSCs uniquely expressed MGP. These findings drove us to further investigate MGP’s role in PV-ADSCs. MGP is a natural binding inhibitor of bone morphogenetic protein 2 (BMP2), a transforming growth factor–beta (TGF–β) superfamily member. MGP could act on BMP2, well known for regulating SMCs proliferation and phenotypic switching, to prevent vascular calcification. BMP2 binds to type I and type II transmembrane serine/threonine kinase receptors, activating SMAD proteins for cell signal transduction to the nucleus. BMP2-mediated signaling pathway could inhibit SMCs contractile marker genes expression. Taken together, the above findings highlight the importance of MGP and BMP2 in SMC biology, which may also play crucial roles in PV-ADSCs.

Our investigation demonstrated that MGP secretion and expression markedly changed during PV-ADSCs differentiation toward SMCs in response to TGF–β. By applying MGP lentivirus inhibition and exogenous MGP, we confirmed MGP’s participation in PV-ADSCs differentiation. Mechanistically, MGP inhibited BMP2 expression, thus inhibiting SMAD1/5/8 phosphorylation. In mouse femoral artery injury model, transplantation of cultured PV-ADSCs with MGP knockdown significantly alleviated neointima formation. These results implied that MGP may potentially serve as a therapeutic target for neointimal hyperplasia.

**Materials and Methods**

**Mice**

C57BL/6 mice aged 8 to 12 weeks were purchased from Shanghai SLAC Laboratory Animal Corporation (Shanghai, China). All animal experiments were approved by the Animal Ethics Committee of the Second Affiliated Hospital of Zhejiang University School of Medicine.

**PV-ADSCs Isolation and Culture**

Briefly, perivascular adipose tissue was dissected from aorta and rinsed with phosphate buffered saline (PBS) for three times. Then, 1-mm³ pieces of adipose tissue were digested with 2 mg/ml collagenase type 1 (Invitrogen, Carlsbad, CA, USA) at 37°C water bath for 30 min. The pellet was resuspended in α-MEM (α-minimal essential medium; Gibco, Rockville, MD, USA) with 20% FBS (fetal bovine serum; Gibco), 10 ng/ml recombinant human leukemia inhibitory factor (Sigma, St. Louis, MO, USA), 5 ng/ml bFGF (basic fibroblast growth factor; R&D systems, Minneapolis, MN, USA), 2 mmol/l L-glutamine (Gibco), and 1% penicillin/streptomycin (Gibco) at 37°C with 5% CO₂. Medium was changed every second day. PV-ADSCs at passages 3 to 4 were used for subsequent experiments.

**Phenotyping of Cultured PV-ADSCs**

PV-ADSCs at passage 3 were resuspended in flow cytometric staining buffer containing the following antibodies: anti-LY6A-PerCP (Abcam, Cambridge, MA, USA), anti-CD29-PerCP (BD Biosciences, Franklin Lakes, NJ, USA), anti-CD105-PE (Abcam), anti-CD34-PE (Invitrogen), anti-CD73-PE (BD Biosciences), and anti-CD45-PE (MultiSciences, Hangzhou, China). LIVE/DEAD™ Fixable Dead Cell Stain Kits (Invitrogen) were applied to distinguish viable cells from dead cells. Cells were analyzed with Beckman Cytoflex.

**Differentiation of PV-ADSCs**

StemPro® Adipogenesis Differentiation Kit (Gibco) and StemPro® Osteogenesis Differentiation Kit (Gibco) were used for adipogenic and osteogenic differentiation of PV-ADSCs, respectively, by following kits’ standard protocols. After 21-day culture, PV-ADSCs were fixed with 4% paraformaldehyde, followed by Oil Red O and Alizarin Red staining. For SMCs differentiation, cultured PV-ADSCs
were changed to medium with 2% FBS and 5 ng/ml TGF-β1 (R&D systems) for indicated time.

**ScRNA-Sequencing Data Analysis**

The data analyzed in this study were from our previous ADSCs’ scRNA database. Subpopulation analysis and differential gene analysis were processed by R package Seurat (version 4.0). scRNA data have been previously uploaded to GEO database reference as GSE172336 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE172336).

**Treatment of PV-ADSCs With MGP/BMP2 and Lentivirus Infection**

PV-ADSCs underwent starvation for 12 to 24 h and then treated with SMCs differentiation medium supplemented with different concentrations of MGP/BMP2 protein (Peprotech, Cranbury, NJ, USA). Medium was changed every second day. Lentivirus targeting mouse Mgp (Mgp shRNA) and scramble shRNA were produced by GeneChem (Shanghai, China). Mgp shRNA sequence: AGT AGC ATT ACT GAA GTA T, scramble shRNA sequence: TTC TCC GAA CGT GTC ACG T. The viruses mixed with Polybrene were used to infect PV-ADSCs for 48 to 72 h and then changed to complete medium.

**Enzyme-Linked Immunosorbent Assay**

PV-ADSCs were seeded in 12-well plate and then treated with 5 ng/ml TGF-β1. Cells cultured without TGF-β1 were served as control. After 3 and 5 days, cell supernatant was collected, respectively, and MGP concentration was measured by using mouse MGP ELISA kit (FineTest, Wuhan, China) as per manufacturer’s instructions.

**Immunofluorescent Staining**

Paraffin sections were first processed to deparaffinage and antigen retrieval before staining. Cells on the coverslips were fixed with 4% paraformaldehyde. The slides were then blocked with 10% donkey serum in PBS for 1 h, followed by incubation with PLIN (1:200, Abcam), LY6A (1:200, Invitrogen), MGP (1:200, Proteintech, Rosemont, IL, USA), ACTA2 (1:200, Abcam), CNN1 (1:200, Abcam), TAGLN (1:200, Abcam), BMP2 (1:1,000, Santa Cruz, Dallas, TX, USA), P-SMAD1/5/8 (1:1,000, Cell Signaling Technology, Boston, MA, USA), and SMAD1 (1:1,000, Cell Signaling Technology) at 4°C overnight. The membranes were washed three times and subsequently incubated with secondary antibodies. Following incubation with enhanced chemiluminescence (ECL) detection solutions, the membranes were placed in the ImageLab machine for exposure.

**Western Blot**

Protein lysate mixed with 1 × SDS loading buffer was loaded on SDS-PAGE gel for electrophoresis and then transferred to the polyvinylidene fluoride (PVDF) membrane. After blocked with 5% to 10% milk in PBS-Tween or TBS-Tween, membranes were incubated with primary antibodies including MGP (1:1,000, Proteintech), ACTA2 (1:2,000, Abcam), CNN1 (1:2,000, Abcam), TAGLN (1:2,000, Abcam), BMP2 (1:1,000, Santa Cruz, Dallas, TX, USA), P-SMAD1/5/8 (1:1,000, Cell Signaling Technology, Boston, MA, USA), and SMAD1 (1:1,000, Cell Signaling Technology) at 4°C overnight. The membranes were washed three times and subsequently incubated with secondary antibodies. Following incubation with enhanced chemiluminescence (ECL) detection solutions, the membranes were placed in the ImageLab machine for exposure.

**Femoral Artery Injury and Perivascular Transplantation of PV-ADSCs**

Detailed procedures were described in previous studies. Briefly, 8- to 12-weeks-old mice were anesthetized, and femoral artery injury was achieved by passing a guide wire back and forth in femoral artery to denude endothelium. After vascular injury, PV-ADSCs were resuspended in Matrigel and delivered to the adventitial side of femoral artery. Four weeks after injury, femoral arteries were collected for further experiments, for example, hematoxylin–eosin staining. Image J software was used for quantification.

**Statistical Analysis**

All statistical analyses in this study were performed by using GraphPad Prism 8.0. Unpaired t test was used to compare the statistical differences between two experimental groups. One-way and two-way analysis of variance (ANOVA) were used to compare the statistical differences among more than two experimental groups. Data were represented as mean ± SD. P < 0.05 was considered statistically significant.

**Results**

**Identification of PV-ADSCs**

PV-ADSCs were isolated and cultured as described previously. Flow cytometry showed that PV-ADSCs highly expressed MSC markers such as LY6A, ITGB1, THY1,
and ENG, while they hardly expressed hematopoietic marker LY5 and endothelial marker PECAM1 (Fig. 1A). Immunofluorescent staining displayed the existence of LY6A⁺ cells not only in the adventitial regions but also in perivascular adipose tissue (Fig. 1B). When treated with adipogenic and osteogenic differentiation medium, significant changes in adipocyte markers (Fig. 1C) and osteocyte markers (Fig. 1E) were observed. Oil Red O (Fig. 1D) and Alizarin Red staining (Fig. 1F) further confirmed PV-ADSCs adipogenic and osteogenic differentiating capacities. The above results identified the existence and MSCs’ properties of PV-ADSCs.
ScRNA Identified a Unique Expression of Mgp in PV-ADSCs

Perivascular and subcutaneous adipose tissue altered neo-intimal hyperplasia reversely after vascular injury. Such opposition might be partially attributed to the distinctive characteristics between SUB-ADSCs and PV-ADSCs. By analyzing scRNA dataset, Mgp was highly expressed in PV-ADSCs compared with SUB-ADSCs. In vitro, qRT-PCR, Western blot, and immunofluorescence confirmed such projection from scRNA analysis.

MGP Expression Significantly Changed During PV-ADSCs Differentiation Toward SMCs in Vitro

Recent studies have confirmed differentiation of PV-ADSCs toward SMCs. To explore whether MGP participates in PV-ADSCs differentiation toward SMCs, we treated PV-ADSCs with 5 ng/ml TGF-β1 for inducing SMC differentiation. SMC markers including ACTA2, TAGLN, and CNN1 markedly increased at both mRNA and protein level in response to TGF-β1. On the contrary, MSC markers such as Ly6a, Thy1, and Kit decreased significantly. Altogether, PV-ADSCs could differentiate toward SMCs in vitro. Along SMCs differentiation at different time points, qRT-PCR demonstrated an elevated Mgp expression, but a decreased intracellular MGP expression as confirmed by Western blot and immunofluorescence. ELISA assays showed a higher concentration of MGP in the supernatant of TGF-β1 treated group. The above results indicated that PV-ADSCs might secrete more MGP during the differentiation toward SMCs.

MGP Regulated PV-ADSCs Differentiation Toward SMCs

To clarify whether MGP regulated SMCs differentiation, MGP was inhibited in PV-ADSCs by using lentivirus encoding Mgp shRNA. The efficiency of MGP inhibition was verified by Western blot and qRT-PCR. When treated with MGP inhibitory virus, the expression of SMC markers in PV-ADSCs greatly declined after TGF-β1 stimulation. Moreover, treatment of exogenous MGP significantly promoted PV-ADSCs differentiation toward SMCs. The above findings showed the involvement of MGP in regulating the differentiation of PV-ADSCs toward SMCs.
Figure 3. PV-ADSCs differentiated toward SMCs in vitro. (A–D) Expression of SMC markers by quantitative polymerase chain reaction (A; n = 4), Western blot (B and C; n = 4), and immunofluorescent staining (D) in PV-ADSCs treated with 5 ng/ml TGF-β1 for 5 days. Scale bar, 100 μm. (E) Quantitative polymerase chain reaction of MSC markers after 5 ng/ml TGF-β1 treatment for 5 days (n = 4). PV-ADSC: perivascular adipose-derived stem cell; SMC: smooth muscle cell; TGF-β1: transforming growth factor–beta 1; MSC: mesenchymal stem cell. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Figure 4. Increased secretion of MGP during PV-ADSCs differentiation toward SMCs. (A–C) Quantitative polymerase chain reaction (A; n = 3), Western blot (B; n = 3), and immunofluorescent staining (C) for MGP expression in PV-ADSCs treated with 5 ng/ml TGF-β1 for different time. Scale bar, 50 μm. (D–E) Western blot (D; n = 3) and ELISA (E; n = 4) for MGP expression in the supernatant of PV-ADSCs after TGF-β1 treatment for 3 and 5 days. MGP: matrix Gla protein; PV-ADSC: perivascular adipose-derived stem cell; SMC: smooth muscle cell; TGF-β1: transforming growth factor–beta 1. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
MGP Promoted PV-ADSCs Differentiation Toward SMCs Via BMP2/SMAD Pathway

MGP/BMP2 signaling pathway regulated the process of vascular calcification and cartilage/bone formation. BMP2, as a member of the TGF-β superfamily, was reported to promote SMCs migration and transdifferentiation. To uncover whether MGP/BMP2 signaling pathway was involved in SMCs differentiation, Bmp2 mRNA and BMP2 protein after MGP knockdown were measured. MGP knockdown enhanced BMP2 expression, verified by qRT-PCR and Western blot. Meanwhile, P-SMAD1/5/8 expression, which was canonical downstream of TGF-β superfamily, was also upregulated after MGP knockdown. On the contrary, BMP2 and P-SMAD1/5/8 expression significantly decreased after MGP treatment at a dose-dependent manner. To further confirm the above hypothesis, BMP2 pathway inhibitor noggin was applied. SMC markers including ACTA2, TAGLN, and CNN1 were significantly suppressed after MGP knockdown, such effect could be attenuated by the treatment of noggin. Furthermore, exogenous BMP2 inhibited SMCs differentiation of PV-ADSCs at a dose-dependent manner. To conclude, MGP regulated SMCs differentiation through BMP2/SMAD pathway.

Knockdown of MGP in PV-ADSCs Alleviated Neointima Formation

Recent research reported that PV-ADSCs could differentiate toward SMCs in vivo and promoted neointimal hyperplasia post vascular injury. Given the role of MGP in SMCs differentiation, we transplanted sh-Mgp PV-ADSCs at the adventitial side of injured femoral arteries. Notably, transplantation of sh-Mgp PV-ADSCs showed less neointimal area and lower neointima/media ratio than that of sh-Scramble PV-ADSCs. Immunofluorescent staining further confirmed the composition of neointima was mainly ACTA2+ SMCs not lymphocytes.

Discussion

Our study elucidated the role and mechanism of MGP in differentiation of PV-ADSCs toward SMCs. This article suggests that MGP and PV-ADSCs may become potential therapeutic targets in vascular remodeling.

ADSCs have been widely studied over last decade. The characteristics of ADSCs could be distinctive upon their origins, including SUB-ADSCs, visceral ADSCs, cardiac ADSCs, perivascular ADSCs, and so on. Among them, the
former two subtypes of ADSCs were paid heavy attention due to their easy access while little effort was carried out on PV-ADSCs. Recently, PV-ADSCs were identified in perivascular adipose tissue by the two independent investigators. Analogous to their findings, our PV-ADSCs expressed similar markers and multiple-lineage differentiation ability. To better illustrate the unique characteristics of PV-ADSCs, we reanalyzed scRNA dataset for the comparison between SUB-ADSCs and PV-ADSCs. Our results confirmed the unique expression of Mgp in PV-ADSCs. MGP was involved in osteogenic differentiation and vascular calcification in the study of vascular SMCs. Recent researches revealed the roles of MGP in the differentiation of stem cells toward ECs and adipocytes. Given its effects on both SMCs and stem cells, as well as its high expression in PV-ADSCs, we hence further investigated its roles in PV-ADSCs. During the differentiation of PV-ADSCs toward SMCs, MGP expression significantly changed. Further knockdown and exogenous overexpression experiments indicated that MGP regulated PV-ADSCs differentiation toward SMCs.

With respect to the underlying mechanism, accumulating evidence has proved the link between MGP and BMP2 in vascular SMCs. It was reported that MGP promoted the maturation and differentiation of vascular SMCs via inhibiting BMP2 pathway. Our study proposed the significance of BMP2/SMAD in regulating PV-ADSCs differentiation. As MGP also occupied various biological effects in SMCs, we did not know whether MGP affected PV-ADSC characteristics through other mechanisms. Neointimal hyperplasia was a common pathological process in vascular remodeling. There have been a large number of studies on macrophages, ECs, SMCs, adventitial stem cells, and neointima formation, all of which are believed to have a contribution to neointima. A recent study verified that PV-ADSCs could differentiate toward SMCs in vivo and promoted neointima formation under vascular injury. Our study demonstrated the contribution of MGP in PV-ADSCs to neointimal hyperplasia in vivo, which provided a supplement to the society.

The present study has few limitations. First, MGP is not uniquely expressed by PV-ADSCs. Another major source of

![Figure 6. MGP promoted PV-ADSCs differentiation toward SMCs via BMP2/SMAD pathway. (A) Quantitative polymerase chain reaction of Bmp2 in PV-ADSCs after Mgp knockdown (n = 3). (B and C) Western blot of BMP2/SMAD pathway protein after Mgp knockdown (B; n = 3) or exogenous MGP recombinant protein addition (C; n = 3). (D) Western blot of SMC markers in PV-ADSCs treated with Noggin and/or Mgp shRNA with TGF-β1 (n = 3). (E) Western blot of SMC markers in PV-ADSCs treated by TGF-β1 with BMP2 recombinant protein (n = 3). MGP: matrix Gla protein; PV-ADSC: perivascular adipose-derived stem cell; SMC: smooth muscle cell; BMP2: bone morphogenetic protein 2; TGF-β1: transforming growth factor–beta 1. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.](image)
MGP is SMCs. Here, we did not investigate the role of SMCs-derived MGP. We also did not know how much PV-ADSCs did contribute to neointimal formation. In addition, as we claimed that PV-ADSCs could secrete MGP, the effect of MGP on other stakeholders such as adventitial stem cells, macrophages, ECs, and so on was not evaluated.

Third, PV-ADSCs lack unique markers, thus difficult to track in vivo. PDGFRA/PDGFRB may be potential markers for PV-ADSCs mentioned in the latest two publications, but it is still under debate. Therefore, there is no definite conclusion whether PV-ADSCs themselves would truly participate in neointimal formation in vivo. At last, the advantage of scRNA-sequencing is not well taken. Cellular subpopulation regarding MGP expression is not addressed. Deeper analysis could be applied if further studies with respect to MGP effects on other PV-ADSCs’ biological function are designed.

**Author Contributions**

Hui Ni contributed to all in vitro experiments, data analysis, and manuscript writing. Chang Liu and Yuwen Chen contributed to figure layout and manuscript revision. Yunrui Lu contributed to scRNA dataset analysis. Yongli Ji contributed to manuscript revision. Meixiang Xiang and Yao Xie contributed to scientific hypothesis, study design, in vivo experiments, critical manuscript revision, and language polishing.

**Ethical Approval**

This study was approved by the Animal Ethics Committee of the Second Affiliated Hospital of Zhejiang University School of Medicine (Hangzhou, China).

**Statement of Human and Animal Rights**

All procedures involving animals were approved by the Animal Ethics Committee of the Second Affiliated Hospital of Zhejiang University School of Medicine (Hangzhou, China).

**Statement of Informed Consent**

There are no human subjects in this article and informed consent is not applicable.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

---

**Figure 7.** Knockdown of MGP in PV-ADSCs Alleviated Neointima Formation. (A) Hematoxylin–eosin staining of the injured femoral artery harvested 4 weeks after PV-ADSCs transplantation. Scale bar, 50 μm. (B) Quantification of neointima/media ratio (n = 5). MGP: matrix Gla protein; PV-ADSCs: perivascular adipose-derived stem cells. ****P < 0.0001.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by the grant from The National Natural Science Foundation of China (NSFC) (Grant Number: 81800427 [Yao Xie], 81870203 [Meixiang Xiang]).

ORCID iD
Hui Ni  https://orcid.org/0000-0003-4125-3795

Supplemental Material
Supplemental material for this article is available online.

References
1. Zhang L, Issa Bhaloo S, Chen T, Zhou B, Xu Q. Role of resident stem cells in vessel formation and arteriosclerosis. Circ Res. 2018;122(11):1608–24.
2. Zük PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7(2):211–28.
3. Ni H, Zhao Y, Ji Y, Shen J, Xiang M, Xie Y. Adipose-derived stem cells contribute to cardiovascular remodeling. Aging. 2019;11(23):11756–69.
4. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L, Norotte C, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3(3):301–13.
5. Miranville A, Heeschen C, Sengenes C, Curat CA, Busse R, Bouloumie A. Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation. 2004;110(3):349–55.
6. Planat-Benard V, Silvestre JS, Cousin B, Andre M, Nibbelink M, Tamatar R, Clergue M, Manneville C, Saillant-Barreau C, Duriez M, Tedgui A, et al. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation. 2004;109(5):656–63.
7. Pan XX, Ruan CC, Liu XY, Kong LR, Ma Y, Wu QH, Li HQ, Sun YJ, Chen AQ, Zhao Q, Wu F, et al. Perivascular adipose tissue-derived stromal cells contribute to vascular remodeling during aging. Aging Cell. 2019;18(4):e12969.
8. Gu W, Nowak WN, Xie Y, Le Bras A, Hu Y, Deng J, Issa Bhaloo S, Lu Y, Yuan H, Fidanis E, Saxena A, et al. Single-Cell RNA-sequencing and metabolism analyses reveal the contribution of perivascular adipose tissue stem cells to vessel remodeling. Arterioscler Thromb Vasc Biol. 2019;39(10):2049–66.
9. Tang J, Wang H, Huang X, Li F, Zhi H, Li Y, He L, Zhang H, Pu W, Liu K, Zhao H, et al. Arterial Seac1 vascular stem cells generate De Novo smooth muscle for artery repair and regeneration. Cell Stem Cell. 2020;26(2):81–96.e4.
10. Schurgers LJ, Uitto J, Reutelingesperger C. Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization. Trends Mol Med. 2013;19(4):217–26.
11. Bostrom K, Zebboudj AF, Yao Y, Lin TS, Torres A. Matrix Gla protein stimulates VEGF expression through increased transforming growth factor-beta1 activity in endothelial cells. J Biol Chem. 2004;279(51):52904–13.
12. Yao Y, Jumabay M, Wang A, Boström KI. Matrix Gla protein deficiency causes arteriovenous malformations in mice. J Clin Invest. 2011;121(8):2993–3004.
13. Speer MY, Yang H-Y, Brabb T, Leaf E, Look A, Lin W-L, Fruttkin A, Dichek D, Giachelli CM. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circulation Research. 2009;104(6):733–41.
14. Li C, Li J, He F, Li K, Li X, Zhang Y. Matrix Gla protein regulates adipogenesis and is serum marker of visceral adiposity. Adipocyte. 2020;9(1):68–76.
15. Zebboudj AF, Imura M, Boström K. Matrix Gla protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem. 2002;277(6):4388–94.
16. Barrett H, O’Keeffe M, Kavanagh E, Walsh M, O’Connor EM. Is matrix Gla protein associated with vascular calcification? A systematic review. Nutrients. 2018;10(4):415.
17. Cai J, Pardali E, Sánchez-Duffhues G, ten Dijke P. BMP signaling in vascular diseases. FEBS Lett. 2012;586(14):1993–2002.
18. King KE, Iyemere VP, Weissberg PL, Shanahan CM. Krüppel-like factor 4 (KLF4/GKLF) is a target of bone morphogenetic proteins and transforming growth factor β1 in the regulation of vascular smooth muscle cell phenotype. J Biol Chem. 2003;278(13):11661–69.
19. Hayashi K, Nakamura S, Nishida W, Sobue K. Bone morphogenetic protein-induced Msx1 and Msx2 inhibit myocardial-dependent smooth muscle gene transcription. Mol Cell Biol. 2006;26(24):9456–70.
20. Fan Y, Chen Y, Zhang J, Yang F, Hu Y, Zhang L, Zeng C, Xu Q. Protective role of RNA helicase DEAD-box protein 5 in smooth muscle cell proliferation and vascular remodeling. Circ Res. 2019;124(10):e84–100.
21. Manka D, Chatterjee TK, Stoll LL, Basford JE, Konanias ES, Srinivasan R, Bogdanov VY, Tang Y, Blomkalns AL, Hui DY, Weintraub NL. Transplanted perivascular adipose tissue accelerates injury-induced neointimal hyperplasia: role of monocyte chemoattractant protein-1. Arterioscler Thromb Vasc Biol. 2014;34(8):1723–30.
22. Spiekeroetter E, Guignabert C, de Jesus Perez V, Alastalo T-P, Powers JM, Wang L, Lawrie A, Ambartsumian N, Schmidt A-M, Berryman M, Ashley RH, et al. S100A4 and bone morphogenetic protein-2 codependently induce vascular smooth muscle cell migration via phospho-extracellular signal-regulated kinase and chloride intracellular channel 4. Circulation Research. 2009;105(7):639–37.
23. Xie Y, Ji Y, Lu Y, Ma Y, Ni H, Shen J, Ma H, Jin C, Chen Y, Lin Y, Xiang M. Distinct characteristics between perivascular adipose tissue and subcutaneous adipose derived stem cells. Diabetes. 2022;71(2):321–28.
24. Yao J, Guihard PJ, Blazquez-Medela AM, Guo Y, Liu T, Boström KI, Yao Y. Matrix Gla protein regulates differentiation of endothelial cells derived from mouse embryonic stem cells. Angiogenesis. 2015;19(1):1–7.
25. Han X, Zhang Z, He L, Zhi H, Li Y, Pu W, Han M, Zhao H, Liu K, Li Y, Huang X, et al. A suite of new Dre recombinase genetic targeting. Cell Stem Cell. 2021;28(6):e1160–76.e1167.
26. Jiang Z, Feng T, Lu Z, Wei Y, Meng J, Lin C-P, Zhou B, Liu C, Zhang H. PDGFβR mesenchymal cells, but not NG2 mural cells, contribute to cardiac fat. Cell Rep. 2021;34(5):108697.